Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Baigent

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
Thrombosis and Haemostasis|March 1, 2013
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart DiseaseRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 24, 2006
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKDMartin Landray, Colin Baigent, Craig Leaper, et al.
Journal of the American College of Cardiology|April 14, 2012
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paperRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Circulation|July 14, 2018
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney DiseaseRichard Haynes, Parminder K Judge, Natalie Staplin, et al.
Thrombosis and Haemostasis|November 15, 2013
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart DiseaseRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Kidney International|July 3, 2014
The 2014International Workshop on Alport SyndromeJeffrey H Miner, Colin Baigent, Frances Flinter, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
European Heart Journal|March 21, 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and preventionPeter Jüni, Sotiris Antoniou, Elena Arbelo, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
Thrombosis and Haemostasis|March 1, 2013
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart DiseaseRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 24, 2006
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKDMartin Landray, Colin Baigent, Craig Leaper, et al.
Journal of the American College of Cardiology|April 14, 2012
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paperRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Circulation|July 14, 2018
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney DiseaseRichard Haynes, Parminder K Judge, Natalie Staplin, et al.
Thrombosis and Haemostasis|November 15, 2013
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart DiseaseRaffaele De Caterina, Steen Husted, Lars Wallentin, et al.
Kidney International|July 3, 2014
The 2014International Workshop on Alport SyndromeJeffrey H Miner, Colin Baigent, Frances Flinter, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
European Heart Journal|March 21, 2025
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and preventionPeter Jüni, Sotiris Antoniou, Elena Arbelo, et al.
Pageof 18